According to IQVIA, sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution achieved annual sales of around USD 113.5 million. Glenmark Pharmaceuticals on Friday ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of latanoprost ophthalmic solution, 0.005% (0.05 mg/mL). Glenmark’s latanoprost ophthalmic solution, 0.005% (0.05 mg/mL) is ...

(RTTNews) - Glenmark Pharmaceuticals Ltd. (GLENMARK.NS), Friday announced that it has introduced Latanoprost Ophthalmic Solution, 0.005 percent, a bioequivalent and therapeutically equivalent ...

ORLANDO — In 2025, improving digital marketing is key to building an ophthalmic practice, according to a speaker at Telling It Like It Is. To improve a practice’s visibility online ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Glenmark Pharmaceuticals' subsidiary has introduced Latanoprost ophthalmic solution, a generic medication for glaucoma, in the US market. The product matches Upjohn US LLC's Xalatan Ophthalmic ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF ... at £470 for one vial of 7.5 mg per 0.3 ml solution – is "similar to the cost of aflibercept." ...

Ointments have the advantage of increased dwell time in the eye, but often patients and parents of children prefer drops, and no therapeutic advantage of one over the other has been demonstrated.

The risk of systemic side effects is greater in infants than in adults due to increased percutaneous drug absorption and lower blood volume. The closed eyes technique of eyedrop administration is ...

Glenmark Pharmaceuticals Inc, USA has launched Latanoprost ophthalmic solution, 0.005% (0.05 mg/mL) in the market, the Mumbai-based drug maker said in a statement. The company’s product is ...

ORLANDO — In this Healio Video Perspective from Telling It Like It Is, Cynthia Matossian, MD, FACS, shared pearls for ophthalmologists who want to take part in clinical trials. A one-time ...

The FDA has expanded the labeling for Izervay (avacincaptad pegol) to include longer-term administration for geographic atrophy secondary to AMD.